Skip to main content
SpringerLink
Log in

Health Economic Benefits of Vasovist®

  • Chapter
Clinical Blood Pool MR Imaging

  • 537 Accesses

Abstract

Research on cost and outcomes has grown to become an integral part of radiology since the first controlled randomized studies in lung and breast cancer were carried out in the 1960s and 1970s. New diagnostic procedures and methods may reduce costs and generate benefits for patients simultaneously, as the introduction of noninvasive magnetic resonance (MR) or computer tomographic (CT) angiography [1] did. However, new methods often increase costs, as they tend not to replace but rather function as an adjunct to existing methods, or their initial costs are higher than those of the methods replaced, or the threshold for the new method is lowered due to a better convenience for the patient or operator [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Budoff MJ, Achenbach S, Duerinckx A (2003) Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography. J Am Coll Cardiol 42:1867–1878

    Article  PubMed  Google Scholar 

  2. Hollingworth (2005) Radiology cost and outcomes studies: Standard practice and emerging methods. AJR Am J Roentgenol 185:833–839

    Article  PubMed  Google Scholar 

  3. Drummond MF, Sculpher MJ, Torrance GW, O’Brian B, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford Medical Publications, Oxford

    Google Scholar 

  4. Phillips C, Thompson G (2003) What is cost-effectiveness. www. evidence-based-medicine.co.uk; volume 1, number 3, http://www.evidence-based-medicine.co.uk/ebmfiles/Whatiscosteffect. pdf (accessed 2007, August 10)

    Google Scholar 

  5. Hunink MGM (1996) Outcomes research and cost-effectiveness analysis in radiology. Eur Radiol 6:615–620

    Article  PubMed  CAS  Google Scholar 

  6. Hunink MGM (1996) Cost-effectiveness research in radiology. Acad Radiol 3:S13–S16

    Article  PubMed  Google Scholar 

  7. Leidl R (2003) Der Effizienz auf der Spur: Eine Einführung in die ökonomische Evaluation. In: Schwartz FW, Badura B, Busse R, Leidl R, Raspe H, Siegrist J, Walter U (eds) Das Public Health Buch, 2nd edn. Urban & Fischer, Munich

    Google Scholar 

  8. Busse R, Orvain J, Valesco M, Perleth M, Drummond M, Gürtner F, Jorgensen T, Jovell A, Malone J, Rüther A, Wild C (2002) Best practice in under taking and reporting health technology assessments. Int J Techn Assessm Health Care 18:361–422

    Google Scholar 

  9. Bock M (2006) Artifacts and limitations of MR angiography. In: Goyen M (ed) MR angiography with blood pool agents. Vasovist® — the first blood pool contrast agent for MR angiography. ABW Wissenschaftsverlag GmbH, pp 38–53

    Google Scholar 

  10. Visser K, Kuntz KM, Donaldson MC, Gazelle GS, Hunink MGM (2003) Pretreatment imaging workup for patients with intermittent daudication: a cost-effectiveness analysis. J Vasc Interv Radiol 14:53–62

    PubMed  Google Scholar 

  11. CPMP Points to consider (2001) Points to consider on the evaluation of diagnostic agents, CPMP/EWP/1119/98

    Google Scholar 

  12. FDA Draft Guideline (2000) Developing medical imaging drugs and biological Products

    Google Scholar 

  13. Hadizadeh DR, Gieseke J, Bayer T, Voth M, Loetsch R, Verrel F, Schild HH, Willinek WA (2007) MR Angiographie der Beingefäße mittels Vasovist: Intra-individueller Vergleich bei Verwendung von arterieller Phase-und Steady State-Bildgebung. Presentation at Röfo 2007, Rofo S1, vol 179

    Google Scholar 

  14. Klessen C, Hein PA, Huppertz A, Voth M, Wagner M, Elgeti T, Kroll H, Hamm B, Taupitz M, Asbach P (2007) First pass whole-body magnetic resonance angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: comparison to gadopentetate dimeglumine. Invest Radiol 42:659–664

    Article  PubMed  Google Scholar 

  15. Wang MS, Haynor DR, Wilson GJ, Leiner T, Maki JH (2007): Maximizing contrast-to-noise ratio in ultra-high resolution peripheral MR angiography using a blood pool agent and parallel imaging. J Magn Reson Imaging 26:580–588

    Article  PubMed  CAS  Google Scholar 

  16. Nikolaou K, Kramer H, Grosse C, Clevert D, Dietrich O, Hartmann M, Chamberlin P, Assmann S, Reiser MF, Schoenberg SO (2006) High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology 241:861–872

    Article  PubMed  Google Scholar 

  17. Linstone HA, Turoff M (eds) (1975) The Delphi method. Techniques and applications. Reading/Mass. (Electronic Version: Turoff M and Linstone H (2002) at http://www.is.njit.edu/pubs/delphibook/, accessed September 23, 2007)

    Google Scholar 

  18. Linstone HA The Delphi technique. In: Fowles J (1978). Handbook of futures research. Westport/Connecticut, London, pp 273–300

    Google Scholar 

  19. Rowe G, Wright G (1999) The Delphi technique as a forecasting tool: issues and analysis. Int J Forecasting 15:377–379

    Article  Google Scholar 

  20. Kobelt G (2002) Health Economics: An introduction to economic evaluation. 2. Edition. Office of Health Economics (www.OHE. org), London

    Google Scholar 

  21. Fineberg HV, Baumann R and Sosman M (1977): Computerized cranial tomography: effect on diagnostic and therapeutic plans. JAMA; 238: 224–227

    Article  PubMed  CAS  Google Scholar 

  22. Gazelle GS, McMahon PM, Siebert U and Beinfeld MT (2005): Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology 235: 361–370

    Article  PubMed  Google Scholar 

  23. Hunink MG and Krestin GP (2002): Study design for concurrent development, assessment, and implementation of new diagnostic imaging technology. Radiology 222: 604–614

    Article  PubMed  Google Scholar 

  24. Leiner T, Kienbaum S (2008) Cost-effectiveness of Gadofosveset in the management of patients with symptomatic peripheral arterial ocdusive disease. TouchBriefings, European Cardiovascular Disease, (in press)

    Google Scholar 

  25. Eisenberg JM (1999) Ten lessons for evidence-based technology assessment. JAMA 282:1865–1869

    Article  PubMed  CAS  Google Scholar 

  26. Beck JR, Kassirer JP, Pauker SG (1982) A convenient approximation of life expectancy (the «DEALE») I. Validation of the method. Am J Med 73:883–888

    Article  PubMed  CAS  Google Scholar 

  27. Holler D (2004) Gesundheitsökonomische Aspekte der Versorgung chronischer Kranker am Beispiel der peripheren arteriellen Verschlusskrankheit. Eine Analyse aus Sicht der Gesellschaft und der Krankenversicherung. Versicherungswissenschaft in Hannover. [Health-economic aspects of care of the chronically ill: the example of peripheral arterial occlusive disease. An analysis from the perspectives of society and the hospital. Actuarial science in Hanover.] Hannoveraner Reihe (Band 23). Graf von der Schulenburg JM (ed) Verlag Versicherungswissenschaft GmbH, Karlsruhe

    Google Scholar 

  28. Institut für das Entgeltsystem im Krankenhaus (InEK) gGmbH (2006) [Institute for the Reimbursement Sytem in Hospitals.] German Diagnosis-Related Groups (G-DRG) Version (V2.4) 2006

    Google Scholar 

  29. Deutsche Krankenhausgesellschaft. Tarif der Deutschen Krankenhausgesellschaft für die Abrechnung erbrachter Leistungen und für die Kostenerstattung vom Arzt an das Krankenhaus (DKG-NT). [German Hospital Society. Tariff of the German Hospital Society for the accounting of services performed and for the reimbursement of the hospital by the doctor.] Stuttgart: W. Kohlhammer Verlag, 2005

    Google Scholar 

  30. Hunink MGM (2007) Whole body imaging: Who does and who does not benefit? Presentation at ECR, 2007

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SCO:SSiS, Zeltinger Strasse 58g, 13465, Berlin, Germany

    Carsten Schwenke

  2. Global Health Economics, Outcomes & Reimbursement Diagnostic Imaging, Bayer Schering Pharma AG, Muellerstrasse 178, 13353, Berlin, Germany

    Susanne Kienbaum

  3. Global Medical Affairs Diagnostic Imaging, Bayer Schering Pharma AG, Müllerstrasse 178, 13353, Berlin, Germany

    Karsten Bergmann

Authors
  1. Carsten Schwenke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Kienbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karsten Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiology, Maastricht University Medical Center, Peter Debijelaan 25, 6229 HX, Maastricht, The Netherlands

    Tim Leiner

  2. University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20251, Hamburg, Germany

    Mathias Goyen

  3. European Business Unit Diagnostic Imaging, Bayer Schering Pharma AG, Muellerstrasse 178, 13353, Berlin, Germany

    Martin Rohrer

  4. Department of Clinical Radiology and Nuclear Medicine University Hospital Mannheim, Medical Faculty Mannheim-University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

    Stefan Schönberg

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwenke, C., Kienbaum, S., Bergmann, K. (2008). Health Economic Benefits of Vasovist® . In: Leiner, T., Goyen, M., Rohrer, M., Schönberg, S. (eds) Clinical Blood Pool MR Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77861-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-77861-5_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-77860-8

  • Online ISBN: 978-3-540-77861-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation